Abivax Shares Rise by 3.25% to Close at 76.3 Euros
French biotech company Abivax ended the session up 3.25% at 76.3 euros, up from 73.9 euros the previous day. This increase is part of a short-term upward trend, with a cumulative gain of 6.12% over the last seven days.
Market Performance and Clinical Trial Updates
The French biotech finished the session up by 3.25% at 76.3 euros, compared to 73.9 euros the previous day. This increase is part of a short-term upward trend, with a cumulative gain of 6.12% over the last seven days. Trading volumes remained moderate, accounting for only 0.06% of the capital, indicating a contained level of activity despite the price increase. Over the past year, the stock has shown an exceptional performance of 778%, significantly outperforming the CAC 40, which has risen by 6.39% over the same period. This development follows the announcements at the beginning of the week regarding positive results from phase 3 ABTECT clinical trials for Obefazimod, the company's flagship drug candidate in the treatment of ulcerative colitis. These additional clinical data, presented during UEG Week in Berlin, have helped sustain investor interest in the stock.
Technical Analysis and Resistance Levels
Technically, the stock is now at its resistance level of 76.50 euros, testing this threshold after rebounding from its support at 67.40 euros. The Relative Strength Index (RSI) at 63 indicates a bullish momentum without immediately signaling an overbought situation. The MACD confirms this positive trend with a main line at 1.52 above its signal line at 1.43, and a slightly positive histogram at 0.08 indicating a moderate acceleration of the upward movement. Analysis of moving averages reveals a favorable technical configuration, with the price significantly above the 50-day moving average (67.29 euros) and the 200-day moving average (22.80 euros). This setup confirms the strength of the underlying trend over the medium and long term. The Bollinger Bands, ranging from 67.68 euros to 74.70 euros, frame the recent fluctuations of the stock, although the price is now slightly above the upper boundary, suggesting a possible extension of the movement.
Caution Advised Despite Technical Progress
Despite this technical progress, some flow indicators call for caution. The negative Chaikin Money Flow at -0.25 indicates that buying volumes remain lower than selling volumes, which may suggest limited participation in the rise. The negative On Balance Volume reinforces this view by showing that accumulation does not fully accompany the price progression. This divergence between price and volumes could suggest a certain fragility in the current bullish movement, even though the overall technical momentum remains positive in the short term.
